Advertisement

Research Article Free access | 10.1172/JCI118734

Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice.

D A Arenberg, S L Kunkel, P J Polverini, M Glass, M D Burdick, and R M Strieter

Department of Internal Medicine (Division of Pulmonary and Critical Medicine), University of Michigan Medical School, Ann Arbor 48109, USA.

Find articles by Arenberg, D. in: JCI | PubMed | Google Scholar

Department of Internal Medicine (Division of Pulmonary and Critical Medicine), University of Michigan Medical School, Ann Arbor 48109, USA.

Find articles by Kunkel, S. in: JCI | PubMed | Google Scholar

Department of Internal Medicine (Division of Pulmonary and Critical Medicine), University of Michigan Medical School, Ann Arbor 48109, USA.

Find articles by Polverini, P. in: JCI | PubMed | Google Scholar

Department of Internal Medicine (Division of Pulmonary and Critical Medicine), University of Michigan Medical School, Ann Arbor 48109, USA.

Find articles by Glass, M. in: JCI | PubMed | Google Scholar

Department of Internal Medicine (Division of Pulmonary and Critical Medicine), University of Michigan Medical School, Ann Arbor 48109, USA.

Find articles by Burdick, M. in: JCI | PubMed | Google Scholar

Department of Internal Medicine (Division of Pulmonary and Critical Medicine), University of Michigan Medical School, Ann Arbor 48109, USA.

Find articles by Strieter, R. in: JCI | PubMed | Google Scholar

Published June 15, 1996 - More info

Published in Volume 97, Issue 12 on June 15, 1996
J Clin Invest. 1996;97(12):2792–2802. https://doi.org/10.1172/JCI118734.
© 1996 The American Society for Clinical Investigation
Published June 15, 1996 - Version history
View PDF
Abstract

The salient feature of solid tumor growth is the strict dependence on local angiogenesis. We have previously demonstrated that IL-8 is an angiogenic factor present in freshly isolated specimens of human non-small cell lung cancer (NSCLC). Using a model of human NSCLC tumorigenesis in SCID mice, we now report that IL-8 acts as a promoter of human NSCLC tumor growth through its angiogenic properties. Passive immunization with neutralizing antibodies to IL-8 resulted in more than 40% reduction in tumor size and was associated with a decline in tumor-associated vascular density and angiogenic activity. IL-8 did not act as an autocrine growth factor for NSCLC proliferation. The reduction in primary tumor size in response to neutralizing antibodies to IL-8 was also accompanied by a trend toward a decrease in spontaneous metastasis to the lung. These data support the notion that IL-8 plays a significant role in mediating angiogenic activity during tumorigenesis of human NSCLC, thereby offering a potential target for immunotherapy against solid tumors.

Version history
  • Version 1 (June 15, 1996): No description
Advertisement
Advertisement